End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.24 BGN | -1.27% | -1.89% | +9.09% |
Feb. 29 | Sopharma AD Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Dec. 20 | Sopharma AD Reports Sales Results for the Month and Eleven Months Ended November 2023 | CI |
Business Summary
Number of employees: 4,721
Sales per Business
BGN in Million | 2023 | Weight | Delta |
---|---|---|---|
Pharmaceutical Goods
83.1
%
| 1,558 | 83.1 % | - |
Pharmaceutical Finished Products
16.9
%
| 317 | 16.9 % | - |
Sales per region
BGN in Million | 2023 | Weight | Delta |
---|---|---|---|
Bulgaria
100.0
%
| 1,874 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 40 | 00-09-30 | |
Director of Finance/CFO | - | 01-12-31 | |
Ivaylo Mechev
ADM | Chief Administrative Officer | - | - |
Chief Tech/Sci/R&D Officer | - | - | |
Ivan Badinski
BRD | Director/Board Member | - | - |
Investor Relations Contact | - | - | |
Maya Taseva
HRO | Human Resources Officer | - | - |
Lora Dicheva
SAM | Sales & Marketing | - | - |
Galina Angelova
LAW | General Counsel | - | - |
S. Katzarova
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 40 | 00-09-30 | |
Bisera Lazarova
BRD | Director/Board Member | - | - |
Director/Board Member | 60 | 99-12-31 | |
Director/Board Member | 58 | 11-07-11 | |
Ivan Badinski
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 179,100,063 | 83,011,557 ( 46.35 %) | 14,328,336 ( 8.000 %) | 46.35 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SOPHARMA TRADING AD 85.00% | 29,136,171 | 85.00% | 90,274,638 $ |
SOPHARMA AD 8.30% | 14,328,336 | 8.30% | 48,833,978 $ |
SOPHARMA PROPERTIES REIT 40.03% | 8,787,132 | 40.03% | 44,728,084 $ |
DOVERIE UNITED HOLDING AD 25.00% | 5,374,600 | 25.00% | 27,179,298 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Medical Distributors
| |
Medical Specialties
| |
Unipharm AD
Unipharm AD Pharmaceuticals: MajorHealth Technology Unipharm AD engages in the development, manufacture and sale of medicinal products. Its products include solid and liquid dosage forms and concentrates for hemodialysis. The company was founded on March 17, 1994 and is headquartered in Sofia, Bulgaria. |
Pharmaceuticals: Major
|
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.09% | 572M | |
-19.49% | 18.13B | |
-29.16% | 11.09B | |
-2.90% | 6.79B | |
-0.60% | 5.57B | |
+10.80% | 5.26B | |
+34.14% | 3.93B | |
-9.43% | 3.75B | |
+4.30% | 3.55B | |
-15.38% | 3.32B |
- Stock
- Equities
- Stock Sopharma AD - Bulgaria S.E.
- Company Sopharma AD